Literature DB >> 3358905

Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia.

R Duncan1, P Kopecková, J Strohalm, I C Hume, J B Lloyd, J Kopecek.   

Abstract

DBA2 mice were inoculated i.p. with 10(5)L1210 cells. Animals subsequently treated with daunomycin (single i.p. dose, 0.25-5.0 mg kg-1) all died. The maximum increase in mean survival time observed was approximately 135%. Animals treated with N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers conjugated to daunomycin (DNM) showed a significant increase in mean survival time when the polymer-drug linkage was biodegradable (i.e., Gly-Phe-Leu-Gly). Such treatment also produced a number of long term survivors (greater than 50 days). In contrast, HPMA copolymer conjugated to DNM via a non-degradable linkage (Gly-Gly) produced no increase in survival time relative to untreated control animals. The effect observed with biodegradable HPMA copolymer-DNM conjugates was dependent on the concentration of conjugated drug administered (optimum greater than 5 mg kg-1); the frequency of administration (multiple doses were more effective than single); the timing of administration (single doses given on days 1 and 3 were most effective); and the site of tumour inoculation and route of drug administration. Biodegradable HPMA copolymer-DNM conjugates administered i.p. were active against L1210 inoculated s.c. at higher doses than required to curb a peritoneal tumour. Under certain experimental conditions polymer-DNM conjugates containing fucosylamine or galactosamine proved more active than conjugates without the carbohydrate moeity. The mechanism of drug-conjugate action in vivo is at present unclear. Radioiodination of polymer showed approximately 75% of polymer-drug conjugate to be excreted 24 h after i.p. administration. Synthesis of HPMA conjugates containing [3H]DNM showed that polymer containing Gly-Gly-[3H]DNM was excreted (60% of radioactivity in the urine, 24 h) in macromolecular form. In contrast polymer containing Gly-Phe-Leu-Gly-[3H]DNM was largely excreted in the form of low molecular weight species.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3358905      PMCID: PMC2246422          DOI: 10.1038/bjc.1988.31

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  A simplified method for determination of amino sugars in glycoproteins.

Authors:  T H Plummer
Journal:  Anal Biochem       Date:  1976-06       Impact factor: 3.365

2.  Controlled release of drug model from N-(2-hydroxypropyl)-methacrylamide copolymers.

Authors:  J Kopecek; P Rejmanová; R Duncan; J B Lloyd
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

3.  Daunorubicin biliary excretion and metabolism in the rat.

Authors:  J C Cradock; M J Egorin; N R Bachur
Journal:  Arch Int Pharmacodyn Ther       Date:  1973-03

Review 4.  Targeting of daunorubicin by association with DNA or proteins: a review.

Authors:  A Trouet; G Jollès
Journal:  Semin Oncol       Date:  1984-12       Impact factor: 4.929

5.  Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats.

Authors:  L W Seymour; R Duncan; J Strohalm; J Kopecek
Journal:  J Biomed Mater Res       Date:  1987-11

6.  Bioaffinity therapy with antibodies and drugs bound to soluble synthetic polymers.

Authors:  B Ríhová; J Kopecek; P Kopecková-Rejmanová; J Strohalm; D Plocová; H Semorádová
Journal:  J Chromatogr       Date:  1986-04-11

7.  Uptake of neoglycoproteins via membrane lectin(s) of L1210 cells evidenced by quantitative flow cytofluorometry and drug targeting.

Authors:  M Monsigny; A C Roche; P Midoux
Journal:  Biol Cell       Date:  1984       Impact factor: 4.458

8.  Studies on the mechanism of action of an antibody-targetted drug-carrier conjugate.

Authors:  M C Garnett; M J Embleton; E Jacobs; R W Baldwin
Journal:  Anticancer Drug Des       Date:  1985-10

9.  Poly-L-aspartic acid as a carrier for doxorubicin: a comparative in vivo study of free and polymer-bound drug.

Authors:  G Pratesi; G Savi; G Pezzoni; O Bellini; S Penco; S Tinelli; F Zunino
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

10.  Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro.

Authors:  R Duncan; P Kopecková-Rejmanová; J Strohalm; I Hume; H C Cable; J Pohl; J B Lloyd; J Kopecek
Journal:  Br J Cancer       Date:  1987-02       Impact factor: 7.640

View more
  11 in total

1.  The Light at the End of the Tunnel-Second Generation HPMA Conjugates for Cancer Treatment.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  Curr Opin Colloid Interface Sci       Date:  2017-07-28       Impact factor: 6.448

Review 2.  Antibody-targeted polymer-bound drugs.

Authors:  B Ríhová
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

3.  Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting.

Authors:  M Nishikawa; A Kamijo; T Fujita; Y Takakura; H Sezaki; M Hashida
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

4.  Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.

Authors:  T K Yeung; J W Hopewell; R H Simmonds; L W Seymour; R Duncan; O Bellini; M Grandi; F Spreafico; J Strohalm; K Ulbrich
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 5.  Polymer conjugates. Pharmacokinetic considerations for design and development.

Authors:  R Duncan; F Spreafico
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

Review 6.  Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review).

Authors:  Yan-Jun Zhong; Li-Hua Shao; Yan Li
Journal:  Int J Oncol       Date:  2012-12-28       Impact factor: 5.650

7.  Protease-activated drug development.

Authors:  Ki Young Choi; Magdalena Swierczewska; Seulki Lee; Xiaoyuan Chen
Journal:  Theranostics       Date:  2012-02-08       Impact factor: 11.556

8.  Comparison of the liver subcellular distribution of free daunomycin and that bound to galactosamine targeted N-(2-hydroxypropyl)methacrylamide copolymers, following intravenous administration in the rat.

Authors:  S R Wedge; R Duncan; P Kopeckova
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

9.  Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma.

Authors:  L W Seymour; K Ulbrich; P S Steyger; M Brereton; V Subr; J Strohalm; R Duncan
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

10.  Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer.

Authors:  Jue Zhang; Jing-Ping Yuan; Qun Wang; Li-Hua Shao; Shao-Ping Liu; Raymond A Firestone; Ya-Ping Hong; Ji-Guo Li; Yan-Chao Xin; Yan Li
Journal:  Oncotarget       Date:  2017-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.